Abstract LB195: AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B

蛋白激酶B PI3K/AKT/mTOR通路 PTEN公司 AKT1型 泛素连接酶 癌症研究 磷酸化 生物 细胞生物学 信号转导 化学 泛素 生物化学 基因
作者
Jia Xu,Xufen Yu,Tiphaine C. Martin,Ankita Bansal,Kakit Cheung,Abigail Lubin,Ηλίας Στρατικόπουλος,Kaitlyn M. Cahuzac,Li Wang,Ling Xie,Royce W. Zhou,Yudao Shen,Xuewei Wu,Shen Yao,Ruifang Qiao,Poulikos I. Poulikakos,Xian Chen,Jing Liu,Jian Jun Jin,Ramon E. Parsons
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): LB195-LB195
标识
DOI:10.1158/1538-7445.am2022-lb195
摘要

Abstract PI3K/AKT/mTOR signaling pathway is one of the most frequently dysregulated pathway in cancer development and the serine/threonine kinase AKT functions as the key node in this pathway to regulate multiple cellular and physiological processes. AKT inhibitors that competitively bind the ATP pocket have been evaluated in clinical trials and have a tolerable toxicity profile with greater efficacy for tumors with pathway mutations; however, many PI3K/AKT pathway mutant tumors remain resistant. Proteolysis targeting chimeras (PROTACs) are a powerful targeted protein degradation technology that hijacks the cellular ubiquitin-proteasome system to induce selective polyubiquitination and degradation of the target proteins. Using this technology, we designed and developed a library of novel small-molecules putative degraders to degrade AKT by recruiting either the cereblon (CRBN) or von Hippel-Lindau (VHL) E3 ligase, that have the ability to degrade AKT in cells and lower downstream signaling to various extents. Though extensive structure-activity relationship studies on various linkers, E3 ligase ligands, and AKT binding moieties, we identified a novel VHL-recruiting AKT degrader, MS21, and characterized it using a panel of 38 cancer cell lines with diverse genotypes and tissue origins. Our results suggest that efficient pharmacologic degradation of AKT phosphorylated on threonine 308 and serine 473 leads to selective inhibition of the growth of tumor cells with alterations of HER2, PIK3CA, PTEN, or AKT1. In these PI3K/PTEN pathway mutant lines, AKT degradation by MS21 was superior to AKT kinase inhibition for reducing cell growth and sustaining lower signaling over many days, and inhibited tumor cell growths through lowering the level of Aurora Kinase B, which we found to be an AKT substrate protein. AKT degradation but not kinase inhibition profoundly lowered Aurora kinase B (AURKB) protein, which is known to be essential for cell division, and induced G2/M arrest and hyperploidy. PI3K activated AKT phosphorylation of AURKB on threonine 73, which protected it from proteasome degradation. A mutant of AURKB (T73E) that mimics phosphorylation and blocks its degradation rescued cells from growth inhibition by MS21. In addition, resistance to MS21 was found to be associated with low levels of baseline AKT phosphorylation in cells as well as mutation of either KRAS or BRAF, and resistance to MS21 could be overcome by the combination treatment of a MEK inhibitor trametinib with MS21, which not only inhibited MEK but also increased AKT phosphorylation and enhanced AKT degradation. Pan-cancer analysis identified that 19% of cases have PI3K/PTEN pathway mutation without RAS pathway mutation, suggesting that these cancer patients could benefit from AKT degrader therapy that leads to loss of AURKB. Citation Format: Jia Xu, Xufen Yu, Tiphaine C. Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M. Cahuzac, Li Wang, Ling Xie, Royce Zhou, Yudao Shen, Xuewei Wu, Shen Yao, Ruifang Qiao, Poulikos I. Poulikakos, Xian Chen, Jing Liu, Jian Jin, Ramon Parsons. AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB195.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
思源的应助被a1262570785采纳,获得10
刚刚
CodeCraft的应助被Big_airplane采纳,获得10
1秒前
qian发布了新的文献求助10
1秒前
Lucas的应助被TT采纳,获得10
1秒前
重逢不太难关注了科研通微信公众号
1秒前
科研通AI6.3的应助被东方浩漫采纳,获得10
2秒前
2秒前
fantasy的应助被zhangmingyang采纳,获得10
2秒前
CipherSage的应助被江sir采纳,获得10
2秒前
茉上发布了新的文献求助20
3秒前
4秒前
fveie完成签到 ,获得积分10
4秒前
一二三只羊完成签到,获得积分20
4秒前
4秒前
Manxi发布了新的文献求助10
5秒前
大模型的应助被明亮的丹烟采纳,获得10
5秒前
5秒前
吴W完成签到,获得积分10
6秒前
hk发布了新的文献求助10
6秒前
酸酸发布了新的文献求助20
6秒前
6秒前
焦恬姿完成签到,获得积分10
6秒前
小远儿同学完成签到,获得积分10
6秒前
星星月月完成签到,获得积分10
6秒前
小牛完成签到,获得积分10
7秒前
powerdeng完成签到,获得积分10
7秒前
miqimiaomiao完成签到,获得积分10
7秒前
7秒前
8秒前
追风发布了新的文献求助10
8秒前
9秒前
9秒前
阿K完成签到,获得积分10
9秒前
9秒前
9秒前
高高采萱完成签到,获得积分20
9秒前
dudu发布了新的文献求助10
10秒前
ccgod发布了新的文献求助30
11秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175943
求助须知:如何正确求助?哪些是违规求助? 9567501
关于积分的说明 21793186
捐赠科研通 7770490
什么是DOI,文献DOI怎么找? 3431935
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477485